Newer drugs keep multiple sclerosis patients out of wheelchairs – expert
نویسندگان
چکیده
منابع مشابه
Epigenetic Drugs for Multiple Sclerosis
There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA...
متن کاملPsychological Changes in Patients With Multiple Sclerosis
Introduction: Multiple Sclerosis (MS) as a stressful event, despite causing negative psychological changes, may lead to positive ones as well. Objective: This study was mainly conducted to examine the implications of posttraumatic growth and demoralization and also to determine the relationship between them in patients with MS. Materials and Methods: This was a cross-sectional study, in which...
متن کاملNewer anti-epileptic drugs.
NEED AND PURPOSE OF REVIEW A number of newer anti-epileptic drugs have been developed in the last few years to improve the treatment outcomes in epilepsy. In this review, we discuss the use of newer anti-epileptic drugs in children. METHODS USED FOR LOCATING, SELECTING, EXTRACTING AND SYNTHESIZING DATA MEDLINE search (1966-2013) was performed using terms newer anti-epileptic drugs, Oxcarbazep...
متن کاملPresenting the Sport Participation Model of Multiple Sclerosis (MS) Patients
Introduction: The study aims to present the sport participation model of multiple sclerosis (MS) patients. Methods: This research was exploratory mixed method (qualitative-quantitative), respectively. The population in the qualitative section of the study consisted of some sports authorities, specialist physicians, sports management professors and a number of athletes with MS illnesses (n ...
متن کاملNewer Antidiabetic Drugs
The current oral blood glucose lowering agents and dietary measures only partially correct the multiple metabolic defects in NIDDM with insulin resistance remaining relatively impervious to treatment Hypoglycaemia and secondary failure are common with presently available sulphonylureas and hence the need for newer blood glucose lowering drugs. In case of NIDDM, a successful new drug should corr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: South African Medical Journal
سال: 2016
ISSN: 2078-5135
DOI: 10.7196/samj.2016.v106i6.11039